Overview

A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

Status:
Recruiting
Trial end date:
2023-05-30
Target enrollment:
Participant gender:
Summary
A Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis
Phase:
Phase 2
Details
Lead Sponsor:
Aristea Therapeutics, Inc.